Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer.

Huixian ZhangLanfang LiLei FengZhen ZhouXin ZhangJianbo FengQiao Liu

Published in: Advances in therapy (2023)

From the perspective of the Chinese healthcare system, this study's findings suggested that first-line TC represents a cost-effective strategy for patients with advanced NSCLC. However, the cost-effectiveness of first-line TC varied across different subgroups when considering predictive biomarkers.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
small cell lung cancer
hiv infected
locally advanced
radiation therapy
rectal cancer
replacement therapy